

31 December 2024

**ValiRx PLC**  
**("ValiRx" or the "Company")**

**Update on proposed sub-license of VAL201**

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that, further to the amendment to the Letter of Intent ("LOI") with TheoremRx Inc ("TheoremRx") announced on 30 October 2024 granting an extension of exclusivity until 31 December 2024, the Company has signed a further amendment to the Letter of Intent ("LOI") with TheoremRx. The exclusivity provided has been extended for a final time period until 31 May 2025.

This final extension has been provided following developments announced by TheoremRx regarding a transaction with a NASDAQ listed company which the board at ValiRx believe may lead to a positive conclusion for the proposed sub-license of VAL201. The LOI and proposed Licence Agreement (as referred to in the announcement of 2 November 2021) remain non-binding and there is no guarantee that this Licence Agreement will be executed or that it will generate material revenues within the expected timeframe or at all.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

**Mark Eccleston, CEO of ValiRx commented** "This final, time limited, extension has been granted to allow TheoremRx to complete their M&A transaction with a NASDAQ listed company, which is required to enable execution of the sub-license of VAL201 to TheoremRx. Further details on the transaction will be made public in due course and we remain supportive of the TheoremRx team and continue to closely monitor their progress."

\*\*\* ENDS \*\*\*

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://valirx.com/s/cc8ef3>

For more information, please contact:

<b>Investor questions on this announcement</b> We encourage all investors to share questions on this announcement via our investor hub	<a href="https://valirx.com/link/lejvQe">https://valirx.com/link/lejvQe</a>
<b>ValiRx plc</b> Dr Mark Eccleston, CEO	<b>Tel: +44 115 784 0026</b> <a href="http://www.valirx.com">www.valirx.com</a> Mark.Eccleston@valirx.com
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b> Liam Murray / Ludovico Lazzaretti	<b>Tel: +44 (0) 20 7213 0880</b>
<b>Shard Capital Partners LLP (Sole Broker)</b> Damon Heath	<b>Tel: +44 (0) 20 7186 9000</b>
<b>V Formation (Public Relations)</b> Lucy Wharton - Senior PR Executive Sue Carr - Director	<b>+44 (0) 115 787 0206</b> <a href="http://www.vformation.biz">www.vformation.biz</a> lucy@vformation.biz sue@vformation.biz

---

## Notes for Editors

### About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: [www.valirx.com](http://www.valirx.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDTBBPTMTJMRI